MedTrace Logo

Spironolactone After Liver Transplant

NCT02883400 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-04-21

Study results available
· View outcomes & findings →

Summary

To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.

Conditions

  • Transplant, Liver

Interventions

DRUG

Spironolactone

spironolactone 25 mg up to 50 mg

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Mark W. Russo, MD, MPH · Charolinas Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02883400 on ClinicalTrials.gov